However, use of glucose-wasting sodium-glucose cotransporter-2 (SGLT2) inhibitors or low-carbohydrate ketogenic diets can minimize the deleterious effects of PI3K–AKT–mTOR inhibitors on both systemic glucose homeostasis and on tumor growth, at least in rodent models [104]. Here, AKT1 is linked to neoplasm.